Human T cell lymphotropic virus type I (HTLV-I), the aetiological agent of adult T cell leukaemia/lymphoma (ATLL)l is associated with the chronic neurodegenerative syndrome termed HTLV-I-associated myelopathy (HAM)2 or tropical spastic paraparesis (TSP). 3 The proliferative synovitis have been reported to be in patients with ATLL4 and HAM/TSP.5 Patients with chronic inflammatory arthropathy are shown to be sero-positive for anti-HTLV-I antibodies (Ab) with a high frequency in the southwest of Japan, which is one of the endemic areas for HTLV-I.6 HTLV-I proviral DNA and viral gene expression have been detected in the synovial cells of polyarthritic patients with anti-HTLV-I.7 Transgenic mice that carry the HTLV-I genome develop chronic arthritis which resembles rheumatoid arthritis.8 It is known that IFNoL possesses a potent antiviral effect in treating viral diseases such as the chronic type C hepatitis and HAM.9 The present study was carried out to determine the efficacy and safety of IFN-ot in treating patients with polyarthritis and anti-HTLV-I Ab.
Seven patients with polyarthritis were administered natural IFN-ot (Otsuka Pharmaceutical, Tokushima, Japan) 2-5 to 4 x 106 IU daily for four weeks, reduced to three times a week for the following four weeks. Patients who responded favourably to this agent were administered for an additional four weeks. Four of the seven serum samples (cases 1-4) were positive for anti-HTLV-I Ab by particle agglutination assay (Serodia-ATL kit, Fujirebio, Japan), and confirmed by Western blotting (Eitest ATL-WB kit, Eisai, Japan), while three of the seven samples (cases 5-7) were negative for anti-HTLV-I Ab. The clinical and laboratory features of these patients are shown in the table.
After eight weeks of IFN-ot treatment, all four seropositive patients exhibited significant improvement in most of the clinical parameters for disease activity (figure). The number of tender and swollen joints decreased significantly from baseline. Swollen Number depicts case. Shadow indicates the normal range.
Letter to the editor spontaneous proliferation of PB-MNC at entry. The elevated spontaneous proliferation was considerably decreased in all three patients. In the three seronegative patients, the spontaneous proliferation of PB-MNC was within the normal range at entry, and they exhibited no significant difference in this parameter as a result of treatment. Although fever, epigastralgia, leukocytopenia and increases in transaminase were found, these adverse effects were not serious. This appears to be the first report to show that IFN-ot is effective clinically in treating polyarthritis patients who are seropositive for anti-HTLV-I Ab. Our present data strongly support the hypothesis that HTLV-I infection may be involved in the development of chronic inflammatory arthropathy in a subset of patients with polyarthritis.
